IL-13Rα1/IL-4Rα | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

3,320 results for “IL-13Rα1/IL-4Rα”

Trials

View all 1307 →

Not yet recruiting

IL-6, IL-12, IL-15 and IL-23 Expression Levels in Rheumatoid Arthritis Patients

80 participants · First posted Aug 16, 2024

A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis

80 participants · First posted Feb 5, 2020

Not yet recruiting

Changes in Salivary Asprosin, IL-39, IL-40 and IL-1β Levels in Diabetic Patients with Periodontitis

176 participants · First posted Dec 16, 2024

Drugs

View all 685 →

IL-4Rα targeting therapy (Atomwise)

IL-25

IL-233

Organizations

View all 18 →

Simcha Il 18, Inc.

United States

Alliance Foundation Trials, LLC

United States

UNIVERSITA' DEGLI STUDI DI ROMA LA SAPIENZA

Italy

News

View all 1310 →

FDA Approves Lilly's Ebglyss (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis

Almirall Launches Phase III Trial Testing Lebrikizumab for Nummular Eczema Treatment

First-in-Class IL-4Rα/ST2 Bispecific Antibody AK139 Advances to Clinical Development for Inflammatory Diseases

Page 1 of 332